Kendall Capital Management Buys 2,025 Shares of Organon & Co. (NYSE:OGN)

Kendall Capital Management grew its stake in Organon & Co. (NYSE:OGN) by 3.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 57,545 shares of the company’s stock after purchasing an additional 2,025 shares during the period. Kendall Capital Management’s holdings in Organon & Co. were worth $859,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Barclays PLC grew its stake in shares of Organon & Co. by 238.0% in the 3rd quarter. Barclays PLC now owns 119,483 shares of the company’s stock valued at $2,285,000 after purchasing an additional 84,136 shares during the period. Weiss Asset Management LP bought a new stake in Organon & Co. during the 3rd quarter worth approximately $32,966,000. Cerity Partners LLC grew its position in Organon & Co. by 94.0% during the 3rd quarter. Cerity Partners LLC now owns 667,340 shares of the company’s stock worth $12,766,000 after acquiring an additional 323,308 shares during the last quarter. Foundry Partners LLC bought a new stake in Organon & Co. during the 3rd quarter worth approximately $7,642,000. Finally, Robeco Institutional Asset Management B.V. bought a new stake in Organon & Co. during the 4th quarter worth approximately $2,263,000. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Stock Up 3.9 %

NYSE:OGN opened at $15.44 on Friday. The stock’s fifty day moving average price is $15.42 and its two-hundred day moving average price is $16.91. Organon & Co. has a 52-week low of $13.87 and a 52-week high of $23.10. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The company has a market cap of $3.98 billion, a price-to-earnings ratio of 4.64, a P/E/G ratio of 0.90 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings data on Thursday, February 13th. The company reported $0.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.09). The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. On average, analysts anticipate that Organon & Co. will post 3.68 EPS for the current year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 13th. Stockholders of record on Monday, February 24th will be paid a $0.28 dividend. This represents a $1.12 dividend on an annualized basis and a dividend yield of 7.26%. The ex-dividend date is Monday, February 24th. Organon & Co.’s dividend payout ratio (DPR) is currently 33.63%.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Barclays decreased their price target on Organon & Co. from $26.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Morgan Stanley decreased their price target on Organon & Co. from $17.00 to $16.00 and set an “equal weight” rating on the stock in a research report on Friday, February 14th. Finally, TD Cowen upgraded Organon & Co. to a “hold” rating in a research report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, two have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $20.80.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.